ACT 017

Drug Profile

ACT 017

Alternative Names: ACT 017

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acticor Biotech
  • Class Antithrombotics; Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action Glycoprotein inhibitors; Platelet membrane glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Stroke

Most Recent Events

  • 05 Feb 2018 Primary adverse events and efficacy data from a phase I trial in Stroke released by Acticor Biotech
  • 05 Feb 2018 Acticor Biotech completes a phase I trial in Stroke (In volunteers) in Netherlands
  • 09 Jan 2018 Acticor Biotech plans a phase II trial for acute ischaemic stroke as an add-on to alteplase in June 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top